Literature DB >> 29998046

Hyperglycemia and chorea.

Masahiro Kashiura1, Haruka Taira1, Shunsuke Amagasa1, Takashi Moriya1.   

Abstract

(A) Computed tomography of the brain showing no abnormal finding. (B) Magnetic resonance imaging of the brain showing a T1-weighted area of hyperintensity in the left putamen, caudate nucleus, and globus pallidum with sparing of the internal capsule (arrow). (C) T2*-weighted image showing hypointensity in the left putamen, caudate nucleus, and globus pallidum (arrowhead). (D) T2-weighted image showing no abnormal finding.

Entities:  

Keywords:  diabetes complications; dyskinesia; haloperidol

Year:  2018        PMID: 29998046      PMCID: PMC6030040          DOI: 10.1002/jgf2.174

Source DB:  PubMed          Journal:  J Gen Fam Med        ISSN: 2189-7948


An 87‐year‐old female who had insulin‐dependent diabetes mellitus with a glycated hemoglobin level of 8.5% presented with altered consciousness due to hyperosmolar hyperglycemic state with blood glucose concentration of 1125 mg/dL and serum osmolality of 341 mOsm/L. One week after the treatment of the hyperglycemia, involving intravenous fluid administration, continuous infusion of insulin, and correction of electrolyte imbalances, the patient gradually regained consciousness but experienced involuntary movements of the right upper limb. Physical examination revealed right semidirected, nonrhythmic, irregular, and twisting movements, consistent with hemichorea (Video S1). A brain computed tomography showed no abnormal findings (Figure 1A). Magnetic resonance imaging of the brain showed a T1‐weighted area of hyperintensity and a T2*‐weighted area of hypointensity in the left caudate nucleus, and a part of the left putamen and globus pallidus, sparing the internal capsule (Figure 1B, arrow; and Figure 1C, arrowhead), with normal findings of T2‐weighted images (Figure 1D). We diagnosed diabetic chorea in this patient based on the clinical course and image findings. The patient's symptoms improved following the administration of haloperidol for a total of 2 months for early symptom control, without recurrence of the hemichorea during the entire follow‐up period of 4 months. Her diabetic control was good with intensive insulin therapy. Diabetic chorea is a neurological complication of hyperglycemia, such as hyperosmolar hyperglycemic state and diabetic ketoacidosis. The symptom improves with treatment of hyperglycemia in most cases. In addition, treatment includes not only dopamine antagonists such as haloperidol, but also tetrabenazine or topiramate.1, 2
Figure 1

A, Computed tomography of the brain showing no abnormal finding. B, Magnetic resonance imaging of the brain showing a T1‐weighted area of hyperintensity in the left putamen, caudate nucleus, and globus pallidum with sparing of the internal capsule (arrow). C, T2*‐weighted image showing hypointensity in the left putamen, caudate nucleus, and globus pallidum (arrowhead). D, T2‐weighted image showing no abnormal finding

A, Computed tomography of the brain showing no abnormal finding. B, Magnetic resonance imaging of the brain showing a T1‐weighted area of hyperintensity in the left putamen, caudate nucleus, and globus pallidum with sparing of the internal capsule (arrow). C, T2*‐weighted image showing hypointensity in the left putamen, caudate nucleus, and globus pallidum (arrowhead). D, T2‐weighted image showing no abnormal finding

CONFLICT OF INTEREST

The authors have stated explicitly that there are no conflicts of interest in connection with this article. Click here for additional data file. Click here for additional data file.
  2 in total

Review 1.  Hyperglycemia-induced hemiballismus hemichorea: a case report and brief review of the literature.

Authors:  Shivakumar Narayanan
Journal:  J Emerg Med       Date:  2010-06-20       Impact factor: 1.484

2.  Diabetic striatal disease: clinical presentation, neuroimaging, and pathology.

Authors:  Yoshinori Abe; Teiji Yamamoto; Tomoko Soeda; Tomohiro Kumagai; Yoshihiro Tanno; Jin Kubo; Tetsuya Ishihara; Soichi Katayama
Journal:  Intern Med       Date:  2009-07-01       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.